Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin A  COVID-19 treatment studies for Vitamin A  C19 studies: Vitamin A  Vitamin A   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Significantly Reduced Retinol Binding Protein 4 (RBP4) Levels in Critically Ill COVID-19 Patients
Vollenberg et al., Nutrients, doi:10.3390/nu14102007
Vollenberg et al., Significantly Reduced Retinol Binding Protein 4 (RBP4) Levels in Critically Ill COVID-19.., Nutrients, doi:10.3390/nu14102007
May 2022   Source   PDF  
  All Studies   Meta
Prospective study of 59 hospitalized COVID-19 patients and 20 matched convalescent control patients in Germany, showing significantly lower vitamin A levels in COVID-19 patients.
Vollenberg et al., 10 May 2022, prospective, Germany, peer-reviewed, 4 authors.
Contact: (corresponding author),,,
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin AAll
Abstract: nutrients Article Significantly Reduced Retinol Binding Protein 4 (RBP4) Levels in Critically Ill COVID-19 Patients Richard Vollenberg 1, * , Phil-Robin Tepasse 1 , Manfred Fobker 2 and Anna Hüsing-Kabar 1 1 2 * Citation: Vollenberg, R.; Tepasse, P.-R.; Fobker, M.; Hüsing-Kabar, A. Significantly Reduced Retinol Binding Protein 4 (RBP4) Levels in Critically Ill COVID-19 Patients. Nutrients 2022, 14, 2007. nu14102007 Academic Editors: Andrea P. Rossi and Marwan El Ghoch Received: 12 April 2022 Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149 Muenster, Germany; (P.-R.T.); (A.H.-K.) Center for Laboratory Medicine, University Hospital Muenster, 48149 Muenster, Germany; Correspondence:; Tel.: +49-25-1834-9198 Abstract: The SARS-CoV-2 virus is the causative agent of the COVID-19 pandemic. The disease causes respiratory failure in some individuals accompanied by marked hyperinflammation. Vitamin A (syn. retinol) can exist in the body in the storage form as retinyl ester, or in the transcriptionally active form as retinoic acid. The main function of retinol binding protein 4 (RBP4), synthesized in the liver, is to transport hydrophobic vitamin A to various tissues. Vitamin A has an important role in the innate and acquired immune system. In particular, it is involved in the repair of lung tissue after infections. In viral respiratory diseases such as influenza pneumonia, vitamin A supplementation has been shown to reduce mortality in animal models. In critically ill COVID-19 patients, a significant decrease in plasma vitamin A levels and an association with increased mortality have been observed. However, there is no evidence on RBP4 in relation to COVID-19. This prospective, multicenter, observational, crosssectional study examined RBP4 (enzyme-linked immunosorbent assay) and vitamin A plasma levels (high-performance liquid chromatography) in COVID-19 patients, including 59 hospitalized patients. Of these, 19 developed critical illness (ARDS/ECMO), 20 developed severe illness (oxygenation disorder), and 20 developed moderate illness (no oxygenation disorder). Twenty age-matched convalescent patients following SARS-CoV-2 infection, were used as a control group. Reduced RBP4 plasma levels significantly correlated with impaired liver function and elevated inflammatory markers (CRP, lymphocytopenia). RBP4 levels were decreased in hospitalized patients with critical illness compared to nonpatients (p < 0.01). In comparison, significantly lower vitamin A levels were detected in hospitalized patients regardless of disease severity. Overall, we conclude that RBP4 plasma levels are significantly reduced in critically ill COVID-19 patients during acute inflammation, and vitamin A levels are significantly reduced in patients with moderate/severe/critical illness during the acute phase of illness. Accepted: 8 May 2022 Published: 10 May 2022 Publisher’s Note: MDPI stays neutral Keywords: COVID-19; retinol binding protein 4; vitamin A; retinol; retinoic acid; ARDS; pneumonia; pandemic; SARS-CoV-2; inflammation with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop